Catalyst Pharmaceuticals, Inc.
355 Alhambra Circle
Suite 1250
Coral Gables, Florida 33134
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention: Suzanne Hayes
Assistant Director
Office of Insurance and Healthcare
VIA EDGAR AND OVERNIGHT COURIER
Ladies and Gentlemen:
On behalf of Catalyst Pharmaceuticals, Inc., a Delaware corporation (the Company), we hereby request, pursuant to Section 477 of the Securities Act of 1933, as amended (the Securities Act), that Post-Effective Amendment No. 1 to the Companys Registration Statement on Form S-3, Registration No. 333-193699, filed with the Securities and Exchange Commission (SEC) on December 6, 2016 (the Post-Effective Amendment) be withdrawn effective immediately. The Post-Effective Amendment is being withdrawn at the request of the SEC and will be replaced by the filing of a new registration statement. The Post-Effective Amendment has not been declared effective and none of the Companys securities has been sold pursuant to the Post-Effective Amendment.
Accordingly, we request that the SEC issue an order granting the withdrawal of the Post-Effective Amendment (Order) effective as of the date hereof or at the earliest practicable date hereafter. Please provide a copy of the Order to Philip B. Schwartz, Esq. of Akerman LLP, via email at philip.schwartz@akerman.com or via facsimile at (305) 349-4833.
This withdrawal affects only the Post-Effective Amendment and does not otherwise affect the Companys Registration Statement on Form S-3, Registration No. 333-193699.
Should you have any questions regarding this request for withdrawal, please contact Philip B. Schwartz at (954) 468-2455.
Very Truly Yours, |
/s/ Alicia Grande |
Alicia Grande |
Chief Financial Officer |
Catalyst Pharmaceuticals, Inc. |
cc: Philip B. Schwartz, Akerman LLP
Dorrie Yale, Securities and Exchange Commission
Mary Beth Breslin, Securities and Exchange Commission